Dr. Golan is a highly qualified medical oncologist and researcher in the field of pancreatic cancer. She specializes in gastrointestinal malignancies, and serves as a director of the Phase I clinical trials unit at Sheba’s Pancreatic Cancer Center.
She has earned a world-renowned reputation for her studies in the field of pancreatic cancer. Her current research trials to test new medicine therapies for metastatic pancreatic cancer are being carried out in conjunction with two of the world’s largest biopharmaceutical companies, AstraZeneca and MSD (Merck).
Dr. Golan’s research offers new hope for patients worldwide with pancreatic cancer, particularly pancreatic adenocarcinoma harboring BRCA mutations. In the clinical trial, more than 3,000 patients were screened, and of them, 154 were randomized and assigned a trial intervention. The results showed that patients who received the POLO trial’s drug treatment did significantly better overall than those who did not receive the drug.
“This treatment [also] exemplifies the advent of ‘precision medicine’ based on a specific genetic biomarker, BRCA 1 & 2,” says Dr. Golan.
- Head, Sheba Pancreatic Cancer Center - SPCC
Conditions and treatment
- gastrointestinal cancer
- pancreatic cancer
- pancreatic adenocarcinoma
- stomach cancer
Education and Training
- MD at Tel Aviv University's School of Medicine, during which she received an Excellence in Research Award from Tel Aviv University.
- Internship in the field of clinical oncology, Sheba Medical Center.
- Clinical Oncology